ID

30575

Descrizione

A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00454532

collegamento

https://clinicaltrials.gov/show/NCT00454532

Keywords

versioni (2)
  1. 16/06/18 16/06/18 -
  2. 16/06/18 16/06/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

16 giugno 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Metastatic Breast Cancer NCT00454532

Inglese

Eligibility Metastatic Breast Cancer NCT00454532

1 moduli  
Criteria
Descrizione

Criteria

women 18 years or older
Descrizione

Gender | Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
histologically confirmed breast cancer
Descrizione

Breast Carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0678222
clinical evidence of metastatic (stage iv) metastasis (other than bone metastasis)
Descrizione

Secondary malignant neoplasm of female breast | Exception Secondary malignant neoplasm of bone

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0346993
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0153690
availability of estrogen and progesterone receptor status
Descrizione

Availability of Estrogen Receptor Status | Availability of Progesterone Receptor Status

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C1516974
UMLS CUI [2,1]
C0470187
UMLS CUI [2,2]
C1514471
at least one measurable disease site defined by recist criteria, 30 days prior to study therapy
Descrizione

Measurable Disease Site Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1515974
UMLS CUI [1,3]
C1265611
for the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. for the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer
Descrizione

Phase Number | Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of female breast

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0205390
UMLS CUI [1,2]
C0237753
UMLS CUI [2,1]
C0677881
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0346993
life expectancy ≥ 12 weeks
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
eastern cooperative oncology group performance status ≤2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
women of child bearing potential must agree to 2 forms of contraception during the course of the trial.
Descrizione

Childbearing Potential Contraceptive methods Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1265611
key exclusion criteria:
Descrizione

Exclusion Criteria Main

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
inability to understand/unwillingness to sign a written informed consent
Descrizione

Informed Consent Unable | Informed Consent Unwilling

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0558080
any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator
Descrizione

Adverse effects Chemotherapy Related | Adverse effects Therapeutic radiology procedure Related | Adverse effects Biological treatment Related | Adverse effects Hormone Therapy Related | Resolution failed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0879626
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C0439849
UMLS CUI [2,1]
C0879626
UMLS CUI [2,2]
C1522449
UMLS CUI [2,3]
C0439849
UMLS CUI [3,1]
C0879626
UMLS CUI [3,2]
C1531518
UMLS CUI [3,3]
C0439849
UMLS CUI [4,1]
C0879626
UMLS CUI [4,2]
C0279025
UMLS CUI [4,3]
C0439849
UMLS CUI [5,1]
C1514893
UMLS CUI [5,2]
C0231175
currently using an investigational agent
Descrizione

Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
clinically significant gastrointestinal abnormalities
Descrizione

Abnormality of the gastrointestinal tract

Tipo di dati

boolean

Alias
UMLS CUI [1]
C4023588
currently using coumadin at therapeutic doses or within 2 weeks of taking study medication
Descrizione

Coumadin Dose Therapeutic | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0699129
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0302350
UMLS CUI [2]
C0013230
concurrent palliative radiation or anti-cancer treatment
Descrizione

Palliative Radiation Therapy | Cancer treatment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3898008
UMLS CUI [2]
C0920425
women who report pregnancy, are breast-feeding or have a positive pregnancy test
Descrizione

Pregnancy | Breast Feeding | Pregnancy test positive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0240802
Ritorna all'inizio della pagina

Similar models

Eligibility Metastatic Breast Cancer NCT00454532

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Gender | Age
Item
women 18 years or older
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Breast Carcinoma
Item
histologically confirmed breast cancer
boolean
C0678222 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Exception Secondary malignant neoplasm of bone
Item
clinical evidence of metastatic (stage iv) metastasis (other than bone metastasis)
boolean
C0346993 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
Availability of Estrogen Receptor Status | Availability of Progesterone Receptor Status
Item
availability of estrogen and progesterone receptor status
boolean
C0470187 (UMLS CUI [1,1])
C1516974 (UMLS CUI [1,2])
C0470187 (UMLS CUI [2,1])
C1514471 (UMLS CUI [2,2])
Measurable Disease Site Quantity
Item
at least one measurable disease site defined by recist criteria, 30 days prior to study therapy
boolean
C1513041 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Phase Number | Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of female breast
Item
for the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. for the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer
boolean
C0205390 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C0677881 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0346993 (UMLS CUI [2,3])
Life Expectancy
Item
life expectancy ≥ 12 weeks
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group performance status ≤2
boolean
C1520224 (UMLS CUI [1])
Childbearing Potential Contraceptive methods Quantity
Item
women of child bearing potential must agree to 2 forms of contraception during the course of the trial.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Informed Consent Unable | Informed Consent Unwilling
Item
inability to understand/unwillingness to sign a written informed consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
Adverse effects Chemotherapy Related | Adverse effects Therapeutic radiology procedure Related | Adverse effects Biological treatment Related | Adverse effects Hormone Therapy Related | Resolution failed
Item
any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator
boolean
C0879626 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
C0879626 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0879626 (UMLS CUI [3,1])
C1531518 (UMLS CUI [3,2])
C0439849 (UMLS CUI [3,3])
C0879626 (UMLS CUI [4,1])
C0279025 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C1514893 (UMLS CUI [5,1])
C0231175 (UMLS CUI [5,2])
Investigational New Drugs
Item
currently using an investigational agent
boolean
C0013230 (UMLS CUI [1])
Abnormality of the gastrointestinal tract
Item
clinically significant gastrointestinal abnormalities
boolean
C4023588 (UMLS CUI [1])
Coumadin Dose Therapeutic | Investigational New Drugs
Item
currently using coumadin at therapeutic doses or within 2 weeks of taking study medication
boolean
C0699129 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0302350 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2])
Palliative Radiation Therapy | Cancer treatment
Item
concurrent palliative radiation or anti-cancer treatment
boolean
C3898008 (UMLS CUI [1])
C0920425 (UMLS CUI [2])
Pregnancy | Breast Feeding | Pregnancy test positive
Item
women who report pregnancy, are breast-feeding or have a positive pregnancy test
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0240802 (UMLS CUI [3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial